OpusPoint Partners: Innovators of Life Science and Healthcare
OpusPoint Partners envisions a better world for mankind. A more viable, stronger and healthier world is achievable with improved delivery of healthcare and medicine. OpusPoint Partners will take the baton in making innovative strides in life science and healthcare. They will make a mark by putting strong investments into pioneering methods that lifts the current banner of healthcare.
Dr. Lindsay Rosenwald and Michael S. Weiss established OpusPoint Partners in 2009. Passionate about biotechnology, the two men have founded several biotech companies together over the years. Rosenwald and Weiss carry more than 40 years of experience under their belts in the fields of life science and biotech investing.
Cougar Biotechnology Inc. is yet another company established by Dr. Lindsay Rosenwald. The company, located in Los Angeles, has established a good portfolio conducting research for new cancer drugs. This has gained the company some attention from researchers and investors. One drug can possibly treat late prostate cancer and on July 10, 2009, Cougar Biotech Labs was sold to Johnson & Johnson for close to one billion dollars.
OpusPoint Partners and Lindsay Rosenwald are devoted to establishing viable partnerships with the biotechnology and investment communities. Keeping integrity amongst relations is one key way of doing this, by remaining open and making honest investments. Leaders of the industry and companies must all recognize the importance of this practice to the strength of their relationships.
Lindsay Rosenwald and OpusPoint Partners are coming together with several researchers, investors and corporations that can join together in providing the world with breakthrough treatments to disease. While lending support to emerging companies and their goals, Dr. Lindsay Rosenwald and OpusPoint Partners will join forces in finding the best research companies on the brink of developing medical innovations.
Dr. Lindsay Rosenwald and OpusPoint Partners aim to challenge the current confines of investing in biotechnology. They are aiming for higher goals in investing and are challenging biotech companies to apply better ethical standards to business and production. OpusPoint Partners is an example of how it is possible to gain attractive rewards without high risks by employing well-rounded practices.
Dr. Rosenwald has had plenty of experience with these ideas. He has been on Wall Street for more than 17 years as a biotechnology entrepreneur. He has also been a key person in the development and recapitalization of several public and private biotech and life sciences companies. He holds a B.S. degree in Finance from Pennsylvania State University and obtained his M.D. from the Temple University School of Medicine.
He also has expertise in financial management of large investment funds. He managed billions of dollars in The Aries Funds (1994 to 2007) and the Orion Fund (2002 to 2006). In the first case, funds have been used to invest in healthcare; in the second case investment has been directed totally to biotechnology, specifically PIPEs.
The founding goal of OpusPoint Partners is to establish a sturdy alliance of partnerships in healthcare and life science that have the same ideals of ethical practice. In the current market, it may be hard to find business leaders who will maintain ethical integrity in their aims for positive clinical outcomes and higher profit.
This is one area where OpusPoint Partners will make a difference. The company has proven its commitments to its shareholders and has also shown its dedication to uphold high principles in drug testing, manufacturing and investigating.
Under the leadership of Michael Weiss and Dr. Lindsay Rosenwald, OpusPoint Partners has a successful future ahead. The combined expertise and experience of both men will help to guide the company in selecting innovative options in healthcare and medicine.
But changing age-old practice in medicine and healthcare will take time, money and great commitment. Trying to keep the ethical standard at a high level will require very strong dedication.
Dr. Rosenwald has no doubts this can be done. OpusPoint Partners, for example, has made very strong strides forward in a short period of time. In less than two years, they were able to financially assist more than 20 companies, proving that using better approaches can certainly yield rewards in the area of drug research and financing.
Dr. Lindsay Rosenwald is a member of the Board of Directors of the Republican Jewish Coalition. In addition, he has close relationships with the biotechnology financing sector. OpusPoint Partners will have a successful development under his direction.
Related posts: